Literature DB >> 21497498

Beneficial effect of docosahexaenoic acid on cholestatic liver injury in rats.

Wen-Ying Chen1, Shih-Yi Lin, Hung-Chuan Pan, Su-Lan Liao, Yu-Han Chuang, Yu-Ju Yen, Szu-Yin Lin, Chun-Jung Chen.   

Abstract

Bile duct obstruction and subsequent cholestasis are associated with hepatocellular injury, cholangiocyte proliferation, stellate cell activation, Kupffer cell activation, oxidative stress, inflammation and fibrosis. Docosahexaenoic acid (DHA) is an essential polyunsaturated fatty acid that has been shown to possess health beneficial effects, including hepatoprotection. However, the molecular mechanism of DHA-mediated hepatoprotection is not fully understood. In the present study, we report the protective effect of DHA on cholestatic liver injury. Cholestasis was produced by bile duct ligation (BDL) in male Sprague-Dawley rats for 3 weeks. Daily administration of DHA was started 2 weeks before injury and lasted for 5 weeks. In comparison with the control group, the BDL group showed hepatic damage as evidenced by histological changes and elevation in serum biochemicals, ductular reaction, fibrosis, inflammation and oxidative stress. These pathophysiological changes were attenuated by chronic DHA supplementation. DHA alleviated BDL-induced transforming growth factor beta-1 (TGF-β1), intereukin-1beta, connective tissue growth factor and collagen expression. The anti-fibrotic effect of DHA was accompanied by reductions in α-smooth muscle actin-positive matrix-producing cells and Smad 2/3 activity critical to the fibrogenic potential of TGF-β1. DHA also attenuated BDL-induced leukocyte accumulation and nuclear factor-κB (NF-κB) activation. Further studies demonstrated an inhibitory effect of DHA on redox-sensitive intracellular signaling molecule extracellular signal-regulated kinase (ERK). Taken together, the hepatoprotective, anti-inflammatory and anti-fibrotic effects of DHA seem to be multifactorial. The beneficial effects of chronic DHA supplementation are associated with anti-oxidative and anti-inflammatory potential as well as down-regulation of NF-κB and transforming growth factor beta/Smad signaling probably via interference with ERK activation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21497498     DOI: 10.1016/j.jnutbio.2010.11.022

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  15 in total

1.  Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/- mice by targeting the TGFβ-Smad3 pathway.

Authors:  Kelli A Lytle; Christopher M Depner; Carmen P Wong; Donald B Jump
Journal:  J Lipid Res       Date:  2015-08-27       Impact factor: 5.922

Review 2.  Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions.

Authors:  Prathima Nandivada; Sarah J Carlson; Melissa I Chang; Eileen Cowan; Kathleen M Gura; Mark Puder
Journal:  Adv Nutr       Date:  2013-11-06       Impact factor: 8.701

3.  An ω-3-enriched diet alone does not attenuate CCl4-induced hepatic fibrosis.

Authors:  Todd R Harris; Sean Kodani; Jun Yang; Denise M Imai; Bruce D Hammock
Journal:  J Nutr Biochem       Date:  2016-09-14       Impact factor: 6.048

4.  A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.

Authors:  J E Eaton; B D Juran; E J Atkinson; E M Schlicht; X Xie; M de Andrade; C S Lammert; V A Luketic; J A Odin; A A Koteish; K V Kowdley; K B Chopra; G M Hirschfield; N P Chalasani; K N Lazaridis
Journal:  Aliment Pharmacol Ther       Date:  2015-03-17       Impact factor: 8.171

5.  Remodeling of the Dermal Extracellular Matrix in a Tissue-Engineered Psoriatic Skin Model by n-3 Polyunsaturated Fatty Acids.

Authors:  Mélissa Simard; Alexe Grenier; Geneviève Rioux; Andréa Tremblay; Isalie Blais; Nicolas Flamand; Roxane Pouliot
Journal:  Biomedicines       Date:  2022-05-06

Review 6.  Lipid emulsions in the treatment and prevention of parenteral nutrition-associated liver disease in infants and children.

Authors:  Prathima Nandivada; Gillian L Fell; Kathleen M Gura; Mark Puder
Journal:  Am J Clin Nutr       Date:  2016-01-20       Impact factor: 7.045

Review 7.  Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy; Kelli A Lytle
Journal:  Adv Nutr       Date:  2015-11-13       Impact factor: 8.701

8.  The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy.

Authors:  Prathima Nandivada; Melissa I Chang; Alexis K Potemkin; Sarah J Carlson; Eileen Cowan; Alison A Oʼloughlin; Paul D Mitchell; Kathleen M Gura; Mark Puder
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

9.  Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells.

Authors:  Xiaoqin Luo; Yan Yang; Tianran Shen; Xilan Tang; Yunjun Xiao; Tangbin Zou; Min Xia; Wenhua Ling
Journal:  Nutr Metab (Lond)       Date:  2012-04-19       Impact factor: 4.169

10.  N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury.

Authors:  Jessica Zúñiga; Milena Cancino; Fernando Medina; Patricia Varela; Romina Vargas; Gladys Tapia; Luis A Videla; Virginia Fernández
Journal:  PLoS One       Date:  2011-12-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.